Disproportionality analysis of adverse neurological and psychiatric reactions with the ChAdOx1 (Oxford-AstraZeneca) and BNT162b2 (Pfizer-BioNTech) COVID-19 vaccines in the United Kingdom
Open accessPublished version of a preprint
The DOI matches its Crossref record; 56 of the 58 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Information on neurological and psychiatric adverse events following immunization (AEFIs) with COVID-19 vaccines is limited. RESEARCH DESIGN & METHODS: We examined and compared neurological and psychiatric AEFIS reports related to BNT162b2 (Pfizer-BioNTech) and ChAdOx1 (Oxford-AstraZeneca) COVID-19 vaccines and recorded in the United Kingdom Medicines and Healthcare products Regulatory Agency between 9 December 2020 and 30 June 2021. RESULTS: As of 30 June 2021, 46.1 million doses of ChAdOx1 and 30.3 million doses of BNT162b2 had been administered. The most frequently reported AEFI was headache with 1,686 and 575 cases per million doses of ChAdOx1 and BNT162b2, respectively. AEFIs more frequently reported after CHAdOx1 compared with BNT162b2 vaccination were Guillain-Barré syndrome (OR, 95% CI = 2.53, 1.82-3.51), freezing (6.66, 3.12-14.22), cluster headache (1.53, 1.28-1.84), migraine (1.23,1.17-1.30), postural dizziness (1.24,1.13-1.37), tremor (2.86, 2.68-3.05), headache (1.40, 1.38-1.43), paresthesia (1.11, 1.06-1.16), delirium (1.85, 1.45-2.36), hallucination (2.20, 1.82-2.66), poor quality sleep (1.53, 1.26-1.85), and nervousness (1.54, 1.26-1.89) Reactions less frequently reported with ChAdOx1 than with BNT162b2 were Bell's palsy (0.47, 0.41-0.55), anosmia (0.58, 0.47-0.71), facial paralysis (0.35, 0.29-0.41), dysgeusia (0.68, 0.62-0.73), presyncope (0.48, 0.42-0.55), syncope (0.63, 0.58-0.67), and anxiety (0.75 (0.67-0.85). CONCLUSION: Neurological and psychiatric AEFIs were relatively infrequent, but each vaccine was associated with a distinctive toxic profile.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Overall, studies of the vector-based vaccines such as the ChAdOx1, have observed a higher incidence of GBS after vaccination compared with the background incidence; whereas, most studies of the mRNA vaccines, such as BNT162b2 and mRNA-1273, have not observed in creases of GBS [14,15,24 -27].”
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · cited 1×
“the mRNA-based BNT162b2 vaccine (Pfizer-BioNTech) [2];”
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
The Medical Dictionary for Regulatory Activities (MedDRA)
Brown, E. G., Wood, L., & Wood, S. (1999) · Drug Safety · doi:10.2165/00002018-199920020-00002 · Cited by 1,390
Voysey, M., Costa Clemens, S. A., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00432-3 · Cited by 1,119
Menni, C., Klaser, K., May, A., Polidori, L., Capdevila, J., Louca, P., Sudre, C. H., Nguyen, L. H., Drew, D. A., Merino, J., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00224-3 · Cited by 1,031 · cited 2×
“Our finding of increased frequency of headaches and migraine with ChAdOx1 agrees with the prospective study of Menni and colleagues [21], where 282,103 persons immunized with BNT162b2 and 345,280 with ChAdOx1 were followed for 12 days after vaccination in the UK.”
BackgroundResultCurrent Concepts in Diagnosis and Treatment of Functional Neurological Disorders
Espay, A. J., Aybek, S., Carson, A., Edwards, M. J., Goldstein, L. H., Hallett, M., LaFaver, K., LaFrance, W. C., Lang, A. E., Nicholson, T., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.1264 · Cited by 786
SCHONBERGER, L. B., BREGMAN, D. J., SULLIVAN-BOLYAI, J. Z., KEENLYSIDE, R. A., ZIEGLER, D. W., RETAILLIAU, H. F., EDDINS, D. L., & BRYAN, J. A. (1979) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a112795 · Cited by 785
Al Kaabi, N., Zhang, Y., Xia, S., Yang, Y., Al Qahtani, M. M., Abdulrazzaq, N., Al Nusair, M., Hassany, M., Jawad, J. S., Abdalla, J., et al. (2021) · JAMA · doi:10.1001/jama.2021.8565 · Cited by 776
Neurologic alterations due to respiratory virus infections
Bohmwald, K., Gálvez, N. M. S., Ríos, M., & Kalergis, A. M. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00386 · Cited by 636
Montastruc, J., Sommet, A., Bagheri, H., & Lapeyre‐Mestre, M. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04037.x · Cited by 517
Cited by
Faksova, K., Walsh, D., Jiang, Y., Griffin, J., Phillips, A., Gentile, A., Kwong, J. C., Macartney, K., Naus, M., Grange, Z., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.01.100 · Cited by 212
Guillain-Barré syndrome in association with COVID-19 vaccination: a systematic review
Abolmaali, M., Rezania, F., Behnagh, A. K., Hamidabad, N. M., Gorji, A., & Mirzaasgari, Z. (2022) · Immunologic Research · doi:10.1007/s12026-022-09316-6 · Cited by 38
Guillain–Barré syndrome and COVID-19 vaccination: a systematic review and meta-analysis
Censi, S. T., Bisaccia, G., Gallina, S., Tomassini, V., & Uncini, A. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12186-7 · Cited by 40
Hadiloo, K., Taremi, S., Safa, S. H., Amidifar, S., & Esmaeilzadeh, A. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107158 · Cited by 15
Eterafi, M., Fouladi, N., Golizadeh, M., Shaker, H., Matin, S., & Safarzadeh, E. (2024) · PLoS ONE · doi:10.1371/journal.pone.0296669 · Cited by 14
Metadata
- Authors
- Otero-Losada, M., Petrovsky, N., Alami, A., Crispo, J. A., Mattison, D., Capani, F., Goetz, C., Krewski, D., & Perez-Lloret, S.
- Affiliations
- Consejo Nacional de Investigaciones Científicas y Técnicas, Universidad Abierta Interamericana-Centro de Altos Estudios en Ciencias Humanas y de La Salud, UAI-CAECIHS CONICET, Buenos Aires, Argentina
- Flinders University (AU)
- University of Ottawa (CA)
- University of British Columbia (CA)
- Consejo Nacional de Investigaciones Científicas y Técnicas (AR)
- Rush University Medical Center (US)
- Observatorio de Salud Pública, Pontificia Universidad Católica Argentina, Buenos Aires, Argentina
- ORCID
- Venue
- Expert Opinion on Drug Safety
- Publisher
- Informa UK Limited
- Published
- 2022-09-07
- Volume
- 22
- Issue
- 4
- Pages
- 343-349
- ISSN
- 1474-0338 (ISSN-L)
- 1744-764X
- OpenAlex
- W4293834588
- Cited by
- 22
- References
- 58
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 9 · 2023: 5 · 2022: 1
- FWCI
- 2.45
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Expert Opinion on Drug Safety (publishedVersion)
- medRxiv (acceptedVersion)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-sa)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Social Sciences › Psychology › Clinical Psychology › COVID-19 and Mental Health
- Keywords
- COVID-19 vaccines, ChAdOx1 nCoV-19 vaccine, BNT162b2, vaccine adverse events, neurological adverse events, psychiatric adverse events, Guillain-Barré syndrome, vaccine safety, disproportionality analysis, United Kingdom, vaccine side effects, Bell's palsy, cluster headache, delirium, hallucinations
- MeSH terms
- COVID-19, COVID-19 Vaccines, BNT162 Vaccine, Headache, Humans, Immunization, Vaccination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Disproportionality analysis of adverse neurological and psychiatric reactions with the ChAdOx1 (Oxford-AstraZeneca) and BNT162b2 (Pfizer-BioNTech) COVID-19 vaccines in the United Kingdom. https://app.cochat.ai/papers/10.1080/14740338.2022.2120607
- The paper
- Otero-Losada, M., Petrovsky, N., Alami, A., Crispo, J. A., Mattison, D., Capani, F., Goetz, C., Krewski, D., & Perez-Lloret, S. (2023). Disproportionality analysis of adverse neurological and psychiatric reactions with the ChAdOx1 (Oxford-AstraZeneca) and BNT162b2 (Pfizer-BioNTech) COVID-19 vaccines in the United Kingdom. Expert Opinion on Drug Safety. https://doi.org/10.1080/14740338.2022.2120607
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.